Journal: Osteologie
ISSN: 1019-1291

Kalzium-Phosphat-Stoffwechsel und Knochen

Issue: Issues of 2017 (Vol. 26): HeIssue 3 2017 (131-191)
Pages: 147-152

  1. Brandenburg VM, Sinha S, Specht P, Ketteler M. Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder. Pediatr Nephrol 2014; 29: 2289-2298. DOI:10.1007/s00467-013-2746-7
  2. Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008; 3: 1139-1143. DOI:10.2215/CJN.00530108
  3. Selye H. The dermatologic implications of stress and calciphylaxis. J Invest Dermatol 1962; 39: 259-275. DOI:10.1038/jid.1962.111
  4. Coates T, Kirkland GS, Dymock RB et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998; 32: 384-391. DOI:10.1053/ajkd.1998.v32.pm9740153
  5. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61: 2210-2217. DOI:10.1046/j.1523-1755.2002.00375.x
  6. Llach F, Velasquez Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001; 38 (5 Suppl 5): S20-S33. DOI:10.1053/ajkd.2001.28113
  7. Block GA. Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 2001; 10: 741-747. DOI:10.1097/00041552-200111000-00003
  8. . Case Report. New Engl J Med 2001; 345: 1119-1124
  9. Brandenburg VM, Kramann R, Rothe H et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant 2017; 32: 126-132.
  10. Nigwekar SU, Zhao S, Wenger J et al. A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. J Am Soc Nephrol 2016; 27: 3421-3429. DOI:10.1681/ASN.2015091065
  11. Hayashi M, Takamatsu I, Kanno Y et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 2012; 27: 1580-1584. DOI:10.1093/ndt/gfr658
  12. Ketteler M, Schlieper G, Floege J. Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 2006; 47: 1027-1034. DOI:10.1161/01.HYP.0000219635.51844.da
  13. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165: 625-630
  14. Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81. DOI:10.1038/386078a0
  15. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-1407. DOI:10.1161/01.ATV.18.9.1400
  16. Schurgers LJ, Spronk HM, Soute BA et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007; 109: 3279-3283. DOI:10.1182/blood-2006-08-040709
  17. Krüger T, Oelenberg S, Kaesler N et al. Warfarin induces cardiovascular damage in mice. Arterioscler Thromb Vasc Biol 2013; 33: 2618-2624. DOI:10.1161/ATVBAHA.113.302244
  18. Schlieper G, Westenfeld R, Krüger T et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011; 22: 387-395. DOI:10.1681/ASN.2010040339
  19. Ketteler M. Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 2005; 14: 337-342. DOI:10.1097/01.mnh.0000172719.26606.6f
  20. Lebreton JP, Joisel F, Raoult JP et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64: 1118-1129. DOI:10.1172/JCI109551
  21. Korkmaz C, Dundar E, Zubaroglu I. Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of long-term steroid use and protein S deficiency. Clin Rheumatol 2002; 21: 66-69. DOI:10.1007/s100670200016
  22. Stenvinkel P, Ketteler M, Johnson R et al. Interleukin-10, IL-6 and TNF-α in end-stage renal disease - the good, the bad and the ugly. Kidney Int 2005; 67: 1216-1233. DOI:10.1111/j.1523-1755.2005.00200.x
  23. Schäfer C, Heiss A, Schwarz A et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366. DOI:10.1172/JCI17202
  24. Ketteler M, Bongartz P, Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833. DOI:10.1016/S0140-6736(03)12710-9
  25. Hermans MM, Brandenburg V, Ketteler M et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007; 72: 202-207. DOI:10.1038/
  26. van der Sluis IM, Boot AM, Vernooij M et al. Idiopathic infantile arterial calcification: clinical presentation, therapy and long-term follow-up. Eur J Pediatr 2006; 165: 590-593. DOI:10.1007/s00431-006-0146-8
  27. Basile C, Montanaro A, Masi M et al. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol 2002; 15: 676-680.
  28. Preiser JC, Ichai C, Orban JC et al. Metabolic response to the stress of critical illness. Br J Anaesth 2014; 113: 945-954. DOI:10.1093/bja/aeu187
  29. Cichone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43: 1104-1108. DOI:10.1053/j.ajkd.2004.03.018
  30. Nigwekar SU, Brunelli SM, Meade D et al. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 2013; 8: 1162-1170. DOI:10.2215/CJN.09880912
  31. Torregrosa JV, Durán CE, Barros X et al. Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia 2012; 32: 329-334.
  32. Shiraishi N, Kitamura K, Miyoshi T et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006; 48: 151-154. DOI:10.1053/j.ajkd.2006.04.062
  33. Brandenburg V, Adragao T, van Dam B et al. Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). Clin Kidney J 2015; 8: 567-571. DOI:10.1093/ckj/sfv056
  34. Joubert P, Ketteler M, Salcedo C, Perello J. Hypothesis: Phytate is an important unrecognised nutrient and potential intravenous drug for preventing vascular calcification. Med Hypotheses 2016; 94: 89-92. DOI:10.1016/j.mehy.2016.07.005

You may also be interested in...


Pablo García de Frutos 1, Pablo Fuentes-Prior 2, Begoña Hurtado 3, Núria Sala3

Thromb Haemost 2007 98 3: 543-556

Matthias Watzka1,2*, Almut Nebel3*, Nour Eddine El Mokhtari 4, Boris Ivandic 5, Jens Müller 1, Stefan Schreiber 3, Johannes Oldenburg1

Thromb Haemost 2007 97 6: 998-1002

Ellen C. M. Cranenburg, Leon J. Schurgers, Cees Vermeer

Thromb Haemost 2007 98 1: 120-125